Cancer is a heterogeneous disease that approximately 1 in 5 people will develop in their lifetime. At Novartis, we are driven by a commitment to keep patients at the center while we innovate and investigate solutions that could advance cancer care. Our goal is simple: to enhance outcomes and quality of life (#QoL) for patients worldwide. Learn more about our innovative approach to cancer care: https://lnkd.in/gYrHBbSy
About us
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
External link for Novartis
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basel, Baselstadt
- Type
- Public Company
- Specialties
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy
Locations
Employees at Novartis
-
Guy Dickinson
Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills
-
David Yee
Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
Updates
-
Bringing radioligand therapy (#RLT) to patients hinges on the readiness of our healthcare systems (HCS). We need: • Access to and availability of diagnostic equipment • Streamlined patient referral processes • More RLT centers • Robust regulatory frameworks • A skilled workforce Only by strengthening these areas can we meet the rising demand for RLT, providing eligible patients the right RLT at the right time to improve outcomes and quality of life (#QoL). Learn more about the potential of RLT to become a new pillar of cancer care: https://lnkd.in/gGC254dP
Preparing HCS for RLT
-
Earlier today, our CEO Vas Narasimhan joined CNBC to talk about this week’s news from the FDA and what it means for #earlybreastcancer patients with Karen Tso and Stephen Sedgwick. Vas also shared his thoughts on our work to reimagine medicine, including investments in cutting-edge cancer treatments like radioligand therapy, how we can reduce costs in the health care system, and our transition into an innovative medicines company over the past six years. It was an exciting day for our team, but what’s even more important is the impact this news will have on patients: tens of thousands of Americans who suffer from early-stage breast cancer will now be able to access treatment that reduces the likelihood of their cancer recurring. We're excited to see how access to these treatments will improve and extend patients’ lives.
-
-
Today’s FDA approval marks a pivotal achievement in our ongoing collaboration with patients, advocates, medical professionals and researchers to help address concerns around disease recurrence in #earlybreastcancer. As we celebrate this new milestone in our 35-year long journey to address the needs of people touched by breast cancer, we reflect on the personal and collective drivers behind our work in this space. Take a look at our sources of inspiration and share with us: what fuels your efforts in #breastcancer? #bcsm #ReimaginingMedicine, together
-
At Novartis, we are committed to raising awareness of the challenges of living with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH). This #PNHAwarenessWeek and beyond, we proudly highlight the work of the Aplastic Anemia & MDS International Foundation and their efforts. Learn more about their mission to support patients living with the disease and improve their quality of life. https://lnkd.in/gZSmTg3t
-
-
Radioligand therapy (#RLT) could be a true paradigm shift in oncology, a potential new pillar of cancer care. However, healthcare system (HCS) readiness for widespread adoption of RLT is behind the speed of innovation. Novartis is partnering with industry and regional HCSs to build capacity for RLT, supporting policies and accelerating referral and funding pathways. Join us at #ESMO2024 where we are leading a panel discussion with industry experts to discuss how we can work together to shape a future where patients with advanced cancers can live better.
Bridging gaps in HCS readiness
-
Cancer is a heterogeneous disease with nearly 20 million people diagnosed in 2022 alone. At Novartis, we are on a mission to develop innovative therapies that improve the future of cancer care. Our broad oncology portfolio addresses pressing unmet needs in a range of advanced cancers, aiming to improve outcomes and enhance quality of life (#QoL) for patients and their loved ones. Learn more about our ongoing efforts in oncology: https://lnkd.in/ggv5umCv
-
As we increase our radioligand therapy (RLT) manufacturing footprint, we are intentionally creating space for continued innovation and growth, driven by the opportunities these advancements may present for patients worldwide. #ReimagineMedicine
Today we announced the construction of two new radioligand therapy (RLT) manufacturing facilities, one of which will produce critical isotopes necessary to create these medicines. As the leader in RLT development and delivery, we remain committed to pioneering RLT science and broadening manufacturing capabilities to support the growing demand for this novel approach to cancer care.
-
At Novartis, we envision a world where preventable cardiovascular deaths are no longer part of our lives. The City Heartbeat Index is being launched today by the World Heart Federation. The Index assessed efforts to understand, prevent and address CVD in 50 cities worldwide, serving as a benchmark for cities on their efforts to protect people’s health. Over half of the world’s population live in cities making this a major step forward to support the development of targeted public health interventions We’re proud to have commissioned the study, independently conducted by Economist Impact. It is by working together, with patients, healthcare professionals, and organizations around the world, that we can have the biggest impact with these learnings. Gain an insight into the key takeaways here and then explore how your city scored: https://lnkd.in/euT4WzFF *Correction: New York = 4/50, Berlin = 5/50
-
Our Q2 performance reflects the continued strong momentum of Novartis. Across the company our teams demonstrated strong commercial execution both in the US and internationally. We also advanced our pipeline, completing new FDA submissions and executing multiple deals to expand our pipeline in RLT and prostate cancer. It’s a great time to be at Novartis as we remain on track for the future. https://lnkd.in/gNdZv2pP #NVSQ224
Affiliated pages
Similar pages
Stock
NVS
NYSE
20 minutes delay
$115.98
0.01 (0.009%)
- Open
- 116.21
- Low
- 115.53
- High
- 116.52
Data from Refinitiv
See more info on